HR positive/HER2 negative advanced or metastatic breast cancer
Clinical trials for HR positive/HER2 negative advanced or metastatic breast cancer explained in plain language.
Never miss a new study
Get alerted when new HR positive/HER2 negative advanced or metastatic breast cancer trials appear
Sign up with your email to follow new studies for HR positive/HER2 negative advanced or metastatic breast cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pfizer drug shows promise against tough cancers
Disease control OngoingThis study tests a new drug called PF-07104091 in people with advanced small cell lung cancer, ovarian cancer, or certain breast cancers that have not responded to prior treatments. The goal is to find the safest dose and see if the drug shrinks tumors, either alone or with other…
Matched conditions: HR POSITIVE/HER2 NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
Phase 2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New drug duo takes on Hard-to-Treat breast cancer
Disease control OngoingThis early-stage trial tests a new drug called OP-1250 combined with an approved targeted therapy, palbociclib, in 60 adults with advanced or metastatic HR-positive, HER2-negative breast cancer. The goal is to find the safest dose and see if the combination can slow tumor growth.…
Matched conditions: HR POSITIVE/HER2 NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
Phase 1 • Sponsor: Olema Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC